Summary
Shares of Sun Pharma, Aurobindo, Lupin, and Zydus Life are in focus following Trump's announcement of a two-year zero tariff policy on generics. US exports constituted significant portions of Aurobindo Pharma's and Sun Pharma's sales in FY26.